Clene Inc. (CLNN)
- Previous Close
0.3465 - Open
0.3465 - Bid 0.3339 x 200
- Ask 0.3432 x 200
- Day's Range
0.3301 - 0.3465 - 52 Week Range
0.2500 - 1.0900 - Volume
118,607 - Avg. Volume
914,293 - Market Cap (intraday)
43.655M - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4700 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
clene.comRecent News: CLNN
Performance Overview: CLNN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLNN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLNN
Valuation Measures
Market Cap
43.65M
Enterprise Value
40.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
54.54
Price/Book (mrq)
3.26
Enterprise Value/Revenue
62.41
Enterprise Value/EBITDA
-0.94
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.33%
Return on Equity (ttm)
-595.47%
Revenue (ttm)
654k
Net Income Avi to Common (ttm)
-49.5M
Diluted EPS (ttm)
-0.4700
Balance Sheet and Cash Flow
Total Cash (mrq)
35M
Total Debt/Equity (mrq)
240.19%
Levered Free Cash Flow (ttm)
-16.17M
Research Analysis: CLNN
Company Insights: CLNN
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CLNN
Daily – Vickers Top Buyers & Sellers for 06/28/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 06/21/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 09/07/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 09/06/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.